Literature DB >> 25739479

[Application of cantharidin, podophyllotoxin, and salicylic acid in recalcitrant plantar warts. A preliminary study].

Daniel López-López1, Carlos Agrasar-Cruz2, Adolfo Bautista-Casasnovas3, Carlos Javier Álvarez-Castro1.   

Abstract

INTRODUCTION: Plantar warts often are refractory to any treatment and can last for decades in adults. Recalcitrant warts are defined as those that have persisted for more than two years, or after at least two treatment modalities.
METHODS: A total of 15 consecutive patients with recalcitrant plantar warts were included in this preliminary study. The treatment consisted of applying one to two sessions that comprised compounding 1% cantharidin, 5% of podophyllotoxin, and 30% salicylic acid (CPS), with an interval between applications of four weeks.
RESULTS: With treatment and subsequent follow-up for six months, there was complete eradication of lesions in 15 patients, eight (53.3%) required a single application of the solution, and seven (46.7%) two applications, with no side effects. Patient satisfaction related to treatment was measured by a visual analog scale (VAS) of 10 cm in length, with an average score 9.73 ± 0.46, and all said they would proceed with the treatment again if necessary.
CONCLUSIONS: Topical treatment by compounding is safe, effective, and a promising therapeutic modality when applied in recalcitrant plantar warts.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25739479

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  4 in total

1.  A Retrospective Study of Clinical Efficacy of Cantharidin Cream for Verruca Plantaris.

Authors:  Xuelin Wu; Yanqing Hu; Yan Lu; Xiuling Ke; Kangxing Liu; Xianyi Zhou; Yongxuan Hu
Journal:  Infect Drug Resist       Date:  2022-07-27       Impact factor: 4.177

2.  Real-life treatment of cutaneous warts with cantharidin podophyllin salicylic acid solution.

Authors:  Anh Ly Nguyen; Koen D Quint; Jan Nico Bouwes Bavinck; Angelina Erceg; Wim J A de Kort; John E M Körver
Journal:  Dermatol Ther       Date:  2019-11-20       Impact factor: 2.851

3.  [Interdigital papilloma exeresis in Primary Care].

Authors:  Víctor Hernández Gombau; Cristina Maldonado Martinez
Journal:  Aten Primaria       Date:  2020-03-14       Impact factor: 1.137

4.  COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.

Authors:  Scott Guenthner; Wendy McFalda; Pearl Kwong; Kimberly Eads; Morgan McCafferty; Jayson Rieger; David K Glover; Cynthia Willson; Patrick Burnett; Melissa Olivadoti
Journal:  Dermatol Ther (Heidelb)       Date:  2021-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.